United States · FDA National Drug Code directory
CARBIDOPA AND LEVODOPA
A source-listed medicine record.
Factual source checks only. This page is not a clinically reviewed monograph. Historical or discontinued records may be included; listing does not confirm approval, current availability or pharmacy stock.
Medicine identity
- Source reference
- 47335-187_540ccc08-0cd2-da03-e063-6394a90a57dd
- Product NDC
- 47335-187
- Form
- TABLET, ORALLY DISINTEGRATING
- Composition / generic term
- CARBIDOPA AND LEVODOPA
- Labeler
- Sun Pharmaceutical Industries, Inc.
- Marketing category
- ANDA
- Marketing start / end (source format)
- 20141215
- Source listing expiry
- 20271231
Source-listed ingredients
- CARBIDOPA — 25 mg/1
- LEVODOPA — 100 mg/1
These values do not establish equivalence or a dose recommendation.
Packages
- 100 TABLET, ORALLY DISINTEGRATING in 1 BOTTLE (47335-187-08) · 47335-187-08
- 1000 TABLET, ORALLY DISINTEGRATING in 1 BOTTLE (47335-187-18) · 47335-187-18
- 30 TABLET, ORALLY DISINTEGRATING in 1 BOTTLE (47335-187-83) · 47335-187-83
- 100 TABLET, ORALLY DISINTEGRATING in 1 BOTTLE (47335-187-88) · 47335-187-88
Source and coverage
Open FDA National Drug Code directory →
Snapshot retrieved: 2026-09-17. This is the acquisition date, not a medical review date.
Clinical information, images and comparisons appear only when separately reviewed for this record. Coverage may be incomplete. Ask a pharmacist or clinician about your treatment.
Browse United States records →